Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

G6PD deficiency: global distribution, genetic variants and primaquine therapy.

Advances in parasitology - 1 Jan 2013

Howes Rosalind E, Battle Katherine E, Satyagraha Ari W, Baird J Kevin, Hay Simon I

Abstract excerpt

Glucose-6-phosphate dehydrogenase (G6PD) is a potentially pathogenic inherited enzyme abnormality and, similar to other human red blood cell polymorphisms, is particularly prevalent in historically malaria endemic countries. The spatial extent of Plasmodium vivax malaria overlaps widely with that of G6PD deficiency; unfortunately the only drug licensed for the radical cure and relapse prevention of P. vivax,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimalarials
Share to Glucosephosphate Dehydrogenase Deficiency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Malaria, Vivax

Share to Mutation

Share to Prevalence

Source

Identifiers

PMID: 23384623
DOI: 10.1016/B978-0-12-407826-0.00004-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

G6PD deficiency: global distribution, genetic variants and primaquine therapy.PMID 23384623Read ↗

Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.Semantic proximity Read ↗

Glucose-6-phosphate dehydrogenase deficiencySemantic proximity Read ↗

Spatial distribution of G6PD deficiency variants across malaria-endemic regions.Semantic proximity Read ↗

G6<scp>PD</scp> deficiency: a classic example of pharmacogenetics with on‐going clinical implicationsSemantic proximity Read ↗

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.Semantic proximity Read ↗

Genetic variants causing G6PD deficiency: Clinical and biochemical data support new WHO classificationSemantic proximity Read ↗

First report of glucose-6-phosphate dehydrogenase (G6PD) variants (Mahidol and Acores) from malaria-endemic regions of northeast India and their functional evaluations in-silico.Semantic proximity Read ↗

Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matterSemantic proximity Read ↗

Glucose-6-Phosphate Dehydrogenase Deficiency Genetic Variants in Malaria Patients in Southwestern Ethiopia.Semantic proximity Read ↗

G6PD deficiency in malaria endemic areas of Nepal.Semantic proximity Read ↗

Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug PrimaquineSemantic proximity Read ↗

Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.